An investigation of the predictability of carboplatin plasma concentrations in children following dosing on the basis of surface area of renal function

Submission date	Recruitment status No longer recruiting	Prospectively registered		
01/07/2001		☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
01/07/2001	Completed	[X] Results		
Last Edited	Condition category	Individual participant data		
01/02/2012	Cancer			

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr - -

Contact details

UKCCCR Register Co-ordinator MRC Clinical Trials Unit 222 Euston Road London United Kingdom NW1 2DA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

Study information

Scientific Title

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Not Specified

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Cancer of brain and nervous system

Interventions

Patients receiving two courses of carboplatin are randomised to one of two groups:

- 1. Group A: Surface area based (course I) followed by renal function based (course II) measurement.
- 2. Group B: Renal function based (course I) followed by surface area based (course II) measurement.

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

Not provided at time of registration

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/01/1993

Completion date

28/02/1997

Eligibility

Key inclusion criteria

- 1. Aged under 18 years
- 2. Receiving carboplatin on at least two occasions
- 3. Being treated according to listed UKCCSG protocols (NB9001, NB9301, NB8702, GC8901, CNS9204, CNS9102, WAG8702)
- 4. Tumour site: Neuroblastoma; Extra-cranial germ cell; Brain

Participant type(s)

Patient

Age group

Child

Upper age limit

18 Years

Sex

Not Specified

Target number of participants

Not provided at time of registration

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/01/1993

Date of final enrolment

28/02/1997

Locations

Countries of recruitment

England

United Kingdom

Study participating centre
UKCCCR Register Co-ordinator
London
United Kingdom
NW1 2DA

Sponsor information

Organisation

Cancer Research UK (CRUK) (UK)

Sponsor details

PO Box 123 Lincoln's Inn Fields London United Kingdom WC2A 3PX +44 (0)207 317 5186 kate.law@cancer.org.uk

Sponsor type

Charity

Website

http://www.cancer.org.uk

ROR

https://ror.org/054225q67

Funder(s)

Funder type

Charity

Funder Name

Cancer Research UK

Alternative Name(s)

CR_UK, Cancer Research UK - London, CRUK

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Funder Name

United Kingdom Children's Cancer Study Group (UKCCSG)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/11/2000		Yes	No